Rocket Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 2/4
Rocket Pharmaceuticals' CEO'su Gaurav Shah, Jan2018 tarihinde atandı, in görev süresi 6.75 yıldır. in toplam yıllık tazminatı $ 8.01M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.8% maaş ve 92.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.24% ine doğrudan sahiptir ve bu hisseler $ 20.77M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.1 yıl ve 6.8 yıldır.
Anahtar bilgiler
Gaurav Shah
İcra Kurulu Başkanı
US$8.0m
Toplam tazminat
CEO maaş yüzdesi | 7.8% |
CEO görev süresi | 6.8yrs |
CEO sahipliği | 1.2% |
Yönetim ortalama görev süresi | 3.1yrs |
Yönetim Kurulu ortalama görev süresi | 6.8yrs |
Son yönetim güncellemeleri
Recent updates
Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?
Sep 23Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review
Sep 15Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix
Jun 28We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely
Jun 09Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)
Apr 05Rocket Pharmaceuticals' Promising Path In Gene Therapy
Mar 01Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth
Nov 07Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering
Oct 03Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate
Aug 25We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate
Jul 22Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs
Jul 08Rocket Pharma: Poised For Growth In The Rare Disease Space
Jun 30Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside
Jan 30We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely
Nov 09Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes
Oct 01Rocket earns Evercore nod after positive data for rare genetic disease
Dec 17Rocket Pharma +33.6% after positive early data in Danon disease Phase 1 trial
Dec 09CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$253m |
Mar 31 2024 | n/a | n/a | -US$249m |
Dec 31 2023 | US$8m | US$625k | -US$246m |
Sep 30 2023 | n/a | n/a | -US$253m |
Jun 30 2023 | n/a | n/a | -US$249m |
Mar 31 2023 | n/a | n/a | -US$237m |
Dec 31 2022 | US$7m | US$598k | -US$222m |
Sep 30 2022 | n/a | n/a | -US$199m |
Jun 30 2022 | n/a | n/a | -US$192m |
Mar 31 2022 | n/a | n/a | -US$172m |
Dec 31 2021 | US$8m | US$590k | -US$169m |
Sep 30 2021 | n/a | n/a | -US$186m |
Jun 30 2021 | n/a | n/a | -US$165m |
Mar 31 2021 | n/a | n/a | -US$155m |
Dec 31 2020 | US$7m | US$540k | -US$140m |
Sep 30 2020 | n/a | n/a | -US$99m |
Jun 30 2020 | n/a | n/a | -US$89m |
Mar 31 2020 | n/a | n/a | -US$82m |
Dec 31 2019 | US$4m | US$480k | -US$77m |
Sep 30 2019 | n/a | n/a | -US$85m |
Jun 30 2019 | n/a | n/a | -US$82m |
Mar 31 2019 | n/a | n/a | -US$79m |
Dec 31 2018 | US$6m | US$414k | -US$75m |
Tazminat ve Piyasa: Gaurav 'nin toplam tazminatı ($USD 8.01M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.54M ).
Tazminat ve Kazançlar: Gaurav şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Gaurav Shah (49 yo)
6.8yrs
Görev süresi
US$8,013,553
Tazminat
Dr. Gaurav D. Shah, M.D., has been an Independent Director at Talaris Therapeutics, Inc. since December 2020. He serves as the Chief Executive Officer and Director of Rocket Pharmaceuticals, Ltd since Janu...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO & Director | 6.8yrs | US$8.01m | 1.24% $ 19.7m | |
Head of R&D | 6.8yrs | US$4.85m | 0.44% $ 7.0m | |
Chief Technical Officer | 2.3yrs | US$4.38m | 0.062% $ 990.4k | |
Chief Medical & Gene Therapy Officer | 6.8yrs | US$3.16m | 0.11% $ 1.7m | |
Chief Financial Officer | less than a year | Veri yok | Veri yok | |
General Counsel | 2.9yrs | US$1.56m | 0.071% $ 1.1m | |
Director of Corporate Communications | no data | Veri yok | Veri yok | |
Chief People Officer | 3.1yrs | Veri yok | Veri yok | |
Senior VP of Clinical Safety & Chief Regulatory Officer | 4.5yrs | Veri yok | Veri yok | |
Chief Business Officer | no data | US$2.82m | 0% $ 0 | |
Chief Commercial Operations & Revenue Officer | less than a year | Veri yok | Veri yok |
3.1yrs
Ortalama Görev Süresi
49yo
Ortalama Yaş
Deneyimli Yönetim: RCKT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.1 yıldır).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO & Director | 6.8yrs | US$8.01m | 1.24% $ 19.7m | |
Independent Director | 10.2yrs | US$399.99k | 0.13% $ 2.0m | |
Independent Director | 6.8yrs | US$429.98k | 0% $ 0 | |
Independent Director | 8.8yrs | US$427.49k | 0% $ 0 | |
Independent Director | less than a year | Veri yok | Veri yok | |
Chairman of the Board | 6.8yrs | US$409.99k | 0.059% $ 937.8k | |
Independent Director | 6.8yrs | US$417.49k | 0.13% $ 2.0m | |
Independent Non-Executive Director | 2.6yrs | US$399.99k | 0% $ 0 | |
Independent Director | 4.5yrs | US$409.99k | 0% $ 0 | |
Director | 6.8yrs | US$399.99k | 0.22% $ 3.5m | |
Independent Non- Executive Director | less than a year | US$568.70k | Veri yok |
6.8yrs
Ortalama Görev Süresi
58yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: RCKT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.8 yıldır).